Mayur Somaiya

Mayur Somaiya

Net worth: 2 M $ as of 2026-05-30

52 year
Finance
Health Technology
Consumer Services

Profile

Mayur Ian Somaiya is currently Chief Financial Officer at NewAmsterdam Pharma Co. NV since 2023.
Former roles include Managing Director & Senior Research Analyst at Piper Sandler & Co. (2010–2013), Managing Director at Thomas Weisel Partners LLC (2003–2009), Managing Director & Senior Analyst at Nomura Securities International, Inc. (2013–2016), Managing Director & Analyst at BMO Capital Markets Corp.
(2016–2018), Managing Director at Piper Sandler Cos., Analyst at Prudential Securities (1997–1999), Senior Analyst at Morgan Stanley & Co. LLC (2000–2002), Consultant at Carson Group, Inc. (New York) (1996–1997), Chief Financial Officer at TCR² Therapeutics, Inc. (2018–2021), and Chief Financial & Business Officer at Elucida Oncology, Inc. (2021–2023).
Education includes an undergraduate degree from New York University, conferred in 1995.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-01-20 58,382 ( 0.05% ) 2 M $ 2026-05-30

Mayur Somaiya active positions

CompaniesPositionStart
FRAZIER LIFESCIENCES ACQUISITION CORPORATION Director of Finance/CFO 2023-10-22

Former positions of Mayur Somaiya

CompaniesPositionEnd
Director of Finance/CFO 2023-06-30
TCR2 THERAPEUTICS INC. Director of Finance/CFO 2021-12-09
Analyst-Equity 2018-03-31
Analyst-Equity 2015-12-31
Analyst-Equity 2013-10-30
See the detail of Mayur Somaiya's experience

Training of Mayur Somaiya

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

98

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Finance

Finance

Finance

Finance

Finance

Finance

Consumer Services

Finance

Health Technology

Health Technology

Finance

Health Technology